It is reasonable to take Emetrol (domperidone) before meals, because absorption of domperidone slows down when taken after meals. If during 2 weeks of continuous use of Emetrol the discomfort does not disappear, it is necessary to consult a doctor. If during the treatment with Emetrol nausea and vomiting persists for more than 48 hours, – it is necessary to consult a physician. Emetrol should be used with caution in patients with the presence of risk factors (hypokalemia, severe hypomagnesemia, organic heart disease, prolongation of Q-T interval in electrocardiogram, liver and/or kidney function disorders). Due to the risk of cardiovascular system complications (ventricular arrhythmias, sudden cardiac arrest in patients over 60 years old when receiving domperidone in doses above 30 mg/day) Emetrol should be used in the lowest effective dose (children, adults). In this case, the risk/benefit ratio of domperidone remains at a favorable level.
Do not use emetrol in patients with lactose intolerance, galactosemia and glucose-galactose malabsorption, because they include lactose.
During pregnancy, use emetrol only if the expected positive effect for the mother exceeds the potential risk to the fetus. Breastfeeding should be stopped during treatment with emetrol, as domperidone penetrates into the breast milk. Emetrol may be used in children over 12 years of age and body weight of 35 kg or more using the minimum effective dose. When using Emetrol, caution should be exercised when driving a vehicle and working with mechanisms, since domperidone may provoke side effects of the central nervous system.
When concomitant use of emetrol with anticholinergic drugs, neutralization of the pharmacological effects of emetrol may occur. Simultaneous use of emetrol and ketoconazole may prolong Q-T interval on electrocardiogram, reflecting the process of ventricular contraction of the heart; therefore, alternative antifungal therapy should be used. Combined use of domperidone with ketoconazole, fluconazole and other medicinal products that inhibit CYP 3A4 isoenzyme may cause increased plasma concentration of domperidone. The listed pharmacological effects of domperidone, peculiarities of its action, low toxicity, minimal side effects among prokinetics with similar mechanism of action allow recommending emetrol for fast and effective drug therapy of gastrointestinal dysfunction symptoms.
Emetrol (domperidone) stops the main mechanism of GIT dysfunction development – disruption of neurohumoral regulation of GIT functions – and eliminates increased activity of aggressors damaging GIT mucosa. Assisting patients in the choice of OTC drug (emetrol) for self-treatment of some manifestations of PD is fully consistent with the principles of rational differentiated pathogenetic therapy of GIT diseases.